Abstract
It is not surprising to find microbiome abnormalities present in psychiatric disorders such as depressive disorders, bipolar disorders, etc. Evolutionary pressure may provide an existential advantage to the host eukaryotic cells in that it survives in an extracellular environment containing non-self cells (e.g., bacteria). This phenomenon is both positive and negative, as with other intercellular processes. In this specific case, the phenomenal amount of information gained from combined bacterial genome could enhance communication between self and non-self cells. This can be coupled to both pathological processes and healthy ones.
In this review, we chose to examine potential associated disorders that may be coupled to the microbiome, from the perspective of their bidirectional communication with eukaryotic cells in the gut. Cognition, being the newest neural networking functionality to evolve, consumes a good amount of organismic energy, 30% of which arises from the gut flora. Furthermore, the mammalian gut is highly innervated and has a highly developed immune component, reflecting brain complexity.
The brain-gut axis uses similar molecular messengers as the brain, which affects bacterial processes as well. Thus, any modification of normal bacterial processes may manifest itself in altered behavior/cognition, originating from the gut. The origin of some disorders associated with this bidirectional communication may be harnessed to restore normal functioning.
MeSH Keywords: Microbiota - Physiology, Psychiatry - History, Depression - Microbiology, Fecal Impaction - Psychology
Neuropsychiatric Disorders
It is slowly becoming evident that neuropsychiatric disorders have a commonality in that they tend to exhibit, simultaneously, a proinflammatory phenomenon [1,2]. This proinflammatory event, which takes place in a microenvironment, may be part of a detection and repair process which becomes evident when a clinical condition brings it to a level of awareness. This proinflammatory state may be due to a number of stimuli, such as the presence of common immune and/or neural mediators at abnormal times and/or concentrations; which may be evidence for a normal intrinsic event that occurs as maintenance or surveillance, such as minor hypoxic events [3–5]. Certainly, such an event, even at the micro-environmental level, could result in the accumulation of degenerated neurons or activated immune cells such as microglia [6], and metabolic chemical residues such as proteins, glycated products, and lipid peroxidation. Indeed, if normally initiated, this proinflammatory state may not have the intrinsic ability to terminate itself, leading to a chronic state of activation, which could become progressively worse [1,7]. Clearly, any intervention which can be brought to bear would profoundly alter this negative cycle. Importantly, this phenomenon should be known to clinicians and be incorporated into their therapeutic strategies.
The incorporation of the gastrointestinal (GI) tract into brain modulation, initiating cognitive impairments, is novel and noteworthy. The gut, in the last 1.5 million years, has become extensively innervated and highly developed for immune surveillance, innate immunity, as well as neuroimmune communications [8,9]. In essence, evolutionary “cultivation” of autonomously functional strains of gut microflora enables prolonged health via regulatory effects at the whole organ level. Importantly, maintenance of normal microbiome components and regulatory activities may be functionally linked to bidirectional communication with host tissues and organs, thereby suggesting retention of common messenger molecules and homologous receptors.
Psychiatric Implications
A legitimate question emerges as to how does this endogenous symbiotic relationship of bacteria and eukaryotic cells become dysfunctional? Since many disorders increase as an individual ages (in plants as well as mammals), a wear and tear hypothesis emerges as well as chemical messenger-associated abnormalities hypothesis [10,11]. Accordingly, intrinsic responses to prolonged environmental stressors, i.e., overproduction of reactive oxygen species (ROS), have been observed to negatively alter ongoing intracellular biochemical and molecular processes [12,13]. Resultant adaptive responses of intrinsic strains of gut microflora appear to mediate necessary changes which underlie the maintenance of homeostatic cohabitation of prokaryotic and eukaryotic components of the gut. These adaptive processes may involve alterations in the intrinsic ratios of the existing subpopulations of gut microflora or the introduction of additional strains. The appearance of similar adaptive phenomena may also be functionally linked to significant dietary alterations.
Morphine Systems
Furthermore, we surmise the endogenous morphine systems may play a key role in gut, gut-brain, and bacterial communication. Opiate processes are noted because of their presence and influence on bacteria, gut, and neurovascular modulation [7,14–20]. In this regard, one may speculate that the pathway to the endogenous synthesis of morphine may be compromised since it involves dopamine as a major precursor, which is well established in psychiatric phenomena [21,22]. Morphine generally exerts a calming action on excitatory activity and behavior, including gut physiological actions [20,23]. Endogenous morphine selectively interacts with a mu-3 like receptor that is coupled to constitutive nitric oxide synthase (cNOS) that occurs in neural and gut tissues [7,20,24–28].
Morphine exerts cell membrane and mitochondrial membrane actions, which appear to be evolutionarily conserved, probably due to the mitochondrion’s bacterial origin [29]. Thus, morphine-nitric oxide synthase (morphine-NOS) coupling to produce NO, is a mitochondrial regulating chemical messenger [22,29–34]. This newer coupling phenomena in eukaryotic cells probably supplemented the already present nitrite reductase driven NO generating system found in prokaryotic and eukaryotic cells, thus producing more NO for mitochondrial modulation in an aerobic environment [35–38]. Moreover, one can speculate that as NO accumulates at the cellular level, energy metabolism would start to diminish and if allowed to continue, more drastic physiological consequences would occur (e.g., constipation); interestingly, an ileus can occur via inducible nitric oxide synthase NO [11,39].
Antibiotics Validate Microbiome and Eukaryotic Bidirectional Communication and Significance in Psychiatric Disorders
As noted, operationally, stereo-selective conformational matching between bacteria and microbiome physiological complexes appears to support the conservation of a critically important set of chemical messengers required for existential regulation of homeostatic cellular processes. The manifestation of acute and/or chronic psychiatric conditions following antibiotic usage may provide unique insights into key etiological factors of major psychiatric syndromes that involve bidirectional communication between the microbiome and the brain [35,39]. Interestingly, one of the first descriptions of the use of antibiotics in understanding cellular processes occurred in 1980 in Prague [40]. This apparently conserved interaction may simply be based on two energy-rich requiring areas, namely, the brain and the gut metabolism [41,42], balancing the same phenomenon. A more global view indicates a potential window of opportunity for development of novel therapeutic agents targeting microbiome neuron immune components, and the influence this has on brain function as a significant causative factor in severe behavioral disorders.
Antibiotics, Probiotics, and Behavior
Some antibiotic-induced side-effects can be referred to as anti-bio-mania since some occur in neural tissues (antimicrobial-induced mania) [30,43]. For example, ciprofloxacin induces a small number of treated patients to develop psychosis [44–47] and once treatment stops, behavior returns to normal. Behavioral changes are not limited just to ciprofloxacin, but also occur with exposure to metronidazole [48], ofloxacin [49], trimethoprim-sulfamethoxazole [50], cotrimoxazole [51], procaine penicillin [52], and clarithromycin [53,54].
Microbes in the gut may also affect the activation state of white blood cells, which can enter the brain compartment and communicate with neurons in an abnormal state and numbers [6]. In the shared commonality of chemical communication with bacteria, antibiotic-induced interactions represent a critical factor in the micro-environmental and in organismic survival [39]. Thus, an enhanced microbial presence or a shift in their microbiome ratio, and an antibiotic presence, may induce behavior disorders. We speculate that in susceptible individuals and in individuals using these agents for extended periods of time, and when antibiotics are use at non-recommended doses, theses antibiotics may turn an acute stress response into one that is chronic and/or one that upsets the balance of bacteria in the gut thereby altering its excitation potential and thus impact the brain [55].
Recent reports have demonstrated that consumption of select probiotic agents may represent a novel treatment method for major depressive disorder using a preclinical rodent model [56,57]. The veracity of these observations is substantiated by another therapeutic treatment, which influences gut, brain-gut communication, e.g., fecal transplantation [57–59]. Depression-associated microbiota have been identified [60,61]. Interestingly, fecal transplantation, representing an old and economical methodology, can induce microbiome modifications in a new host’s GI tract flora leading to behavioral changes, providing a new treatment for neurobehavioral disorders [59,62–67]. This 1,700 year old technique appears to be gaining in use because, as these reports indicate, it can be used to treat GI-associated maladies as well diseases such as Crohn’s disease. It has recently gained credible status as a novel approach to treat metabolic autoimmune diseases as well as psychiatric disorders [59,62–71]. This approach has been reported to positively affect autism as well [72,73]. However, there are reports of inducing behavioral abnormalities, such as depression, via this treatment modality [8]. In summary, the literature demonstrates that the microbiome does affect host processes via, in all probability, common chemical messengers whose appearance and synthesis depends on normal ratios of specific bacteria, which can be modified via the microbiome environment, e.g., diet, stress via the CNS, etc.
Conclusions
A contemporary understanding of mental abnormalities is largely based on a search for genetic contexts that involve these disorders [74,75] and their interactions with the environment [75,76]. This approach is also reflected in current treatment guidelines. Davidson (2009) published an analysis of six sets of guidelines for treatment of depressive disorder from Europe and the Americas [77]. Current first-line treatment recommendations for moderate major depressive disorder include antidepressant monotherapy, psychotherapy, and a combination of both. Severe depression may require the combination of an antidepressant and an antipsychotic, electroconvulsive therapy, or the combination of an antidepressant and psychotherapy. Other medications play a very limited role in the treatment of depression. Most of the treatment guidelines rely on current pharmacotherapy; the issuance of lifestyle modifications is regarded as supportive therapy. However, current literature provides evidence for specific lifestyle choices and the alleviation of depressive symptoms [78,79]. In this regard, lifestyle issues targeting enhanced and appropriate bidirectional communication of the microbiome with the host tissue is also becoming very important in light of our understanding of the shared chemical messengers and signaling systems that appear to integrate gut-brain regulatory processes. Finally, the potential association of aberrant metabolic and communication processes in the microbiome to the etiology and persistence of psychiatric disorders may lead to the development of novel treatment strategies and therapeutic agents directly focused on re-establishing a functionally competent microbiome.
Footnotes
Source of support: In part, the study was funded by the Department of Psychiatry, Charles University, Prague, Czech Republic
References
- 1.Esch T, Stefano GB. Proinflammation: A common denominator or initiator of different pathophysiological disease processes. Med Sci Monit. 2002;8(5):HY1–9. [PubMed] [Google Scholar]
- 2.Esch T, Stefano GB, Fricchione GL, Benson H. The role of stress in neurodegenerative diseases and mental disorders. Neuro Endocrinol Lett. 2002;23(3):199–208. [PubMed] [Google Scholar]
- 3.Stefano GB, Kream RM. Hypoxia defined as a common culprit/initiation factor in mitochondrial-mediated proinflammatory processes. Med Sci Monit. 2015;21:1478–84. doi: 10.12659/MSM.894437. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Snodgrass RG, Boss M, Zezina E, et al. Hypoxia potentiates palmitate-induced pro-inflammatory activation of primary human macrophages. J Biol Chem. 2016;291(1):413–24. doi: 10.1074/jbc.M115.686709. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Yang C, Jiang L, Zhang H, et al. Analysis of hypoxia-induced metabolic reprogramming. Methods Enzymol. 2014;542:425–55. doi: 10.1016/B978-0-12-416618-9.00022-4. [DOI] [PubMed] [Google Scholar]
- 6.Stefano GB, Bilfinger TV, Fricchione GL. The immune neuro-link and the macrophage: Postcardiotomy delirium, HIV-associated dementia and psychiatry. Prog Neurobiol. 1994;42:475–88. doi: 10.1016/0301-0082(94)90048-5. [DOI] [PubMed] [Google Scholar]
- 7.Stefano GB, Scharrer B. Endogenous morphine and related opiates, a new class of chemical messengers. Adv Neuroimmunol. 1994;4:57–68. doi: 10.1016/s0960-5428(05)80001-4. [DOI] [PubMed] [Google Scholar]
- 8.Zheng P, Zeng B, Zhou C, et al. Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host’s metabolism. Mol Psychiatry. 2016;21(6):786–96. doi: 10.1038/mp.2016.44. [DOI] [PubMed] [Google Scholar]
- 9.Petra AI, Panagiotidou S, Hatziagelaki E, et al. Gut-microbiota-brain axis and its effect on neuropsychiatric disorders with suspected immune dysregulation. Clin Ther. 2015;37(5):984–95. doi: 10.1016/j.clinthera.2015.04.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Makman MH, Stefano GB. Neuroregulatory mechanisms in aging. Oxford, England: Pergamon Press; 1993. [Google Scholar]
- 11.Stefano GB, Kream RM. Aging reversal and healthy longevity is in reach: Dependence on mitochondrial DNA Heteroplasmy as a key molecular target. Med Sci Monit. 2017;23:2732–35. doi: 10.12659/MSM.902515. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Yu T, Robotham JL, Yoon Y. Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl Acad Sci USA. 2006;103(8):2653–58. doi: 10.1073/pnas.0511154103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Yu T, Jhun BS, Yoon Y. High-glucose stimulation increases reactive oxygen species production through the calcium and mitogen-activated protein kinase-mediated activation of mitochondrial fission. Antioxid Redox Signal. 2011;14(3):425–37. doi: 10.1089/ars.2010.3284. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Simon EJ, Vanpraag D. Selective inhibition of synthesis of ribosomal RNA in Escherichia coli by levorphanol. Proc Natl Acad Sci USA. 1964;51:1151–58. doi: 10.1073/pnas.51.6.1151. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Simon EJ, Vanpraag D. Inhibition of RNA synthesis in Escherichia coli by levorphanol. Proc Natl Acad Sci USA. 1964;51:877–83. doi: 10.1073/pnas.51.5.877. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Zucker-Franklin D, Elsbach P, Simon EJ. The effect of morphine analog levorphanol on phagocytosing leukocytes. Lab Invest. 1971;25:415–21. [PubMed] [Google Scholar]
- 17.Wurster N, Elsbach P, Rand J, Simon EJ. Effects of levorphanol on phospholipid metabolism and composition in Escherichia coli. Biochim Biophys Acta. 1971;248(2):282–92. doi: 10.1016/0005-2760(71)90016-6. [DOI] [PubMed] [Google Scholar]
- 18.Simon EJ, Hiller JM, Edelman I. Stereospecific binding of the potent narcotic analgesic (3H) Etorphine to rat-brain homogenate. Proc Natl Acad Sci USA. 1973;70(7):1947–49. doi: 10.1073/pnas.70.7.1947. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Persky-Brosh S, Young JR, Holland MJ, Simon EJ. Effect of morphine analogues on chemotaxis in Escherichia coli. J Gen Microbiol. 1978;107(1):53–58. doi: 10.1099/00221287-107-1-53. [DOI] [PubMed] [Google Scholar]
- 20.Stefano GB, Zhu W, Cadet P, Mantione K. Morphine enhances nitric oxide release in the mammalian gastrointestinal tract via the m3 opiate receptor subtype: A hormonal role for endogenous morphine. J Physiolo Pharmacol. 2004;55(1 Pt 2):279–88. [PubMed] [Google Scholar]
- 21.Kream RM, Stefano GB. De novo biosynthesis of morphine in animal cells: An evidence-based model. Med Sci Monit. 2006;12(10):RA207–19. [PubMed] [Google Scholar]
- 22.Kream RM, Sheehan M, Cadet P, et al. Persistence of evolutionary memory: Primordial six-transmembrane helical domain mu opiate receptors selectively linked to endogenous morphine signaling. Med Sci Monit. 2007;13(12):SC5–6. [PubMed] [Google Scholar]
- 23.Stefano GB, Goumon Y, Casares F, et al. Endogenous morphine. Trends Neurosci. 2000;9:436–42. doi: 10.1016/s0166-2236(00)01611-8. [DOI] [PubMed] [Google Scholar]
- 24.Kream RM, Stefano GB, Rtacek R. Psychiatric implications of endogenous morphine: Up-to-date review. Folia Biol (Praha) 2010;56:231–41. [PubMed] [Google Scholar]
- 25.Kream RM, Mantione KJ, Sheehan M, Stefano GB. Morphine’s chemical messenger status in animals. Activitas Nervosa Superior Rediviva. 2009;51(1–2):153–61. [Google Scholar]
- 26.Mantione KJ, Cadet P, Zhu W, et al. Endogenous morphine signaling via nitric oxide regulates the expression of CYP2D6 and COMT: Autocrine/paracrine feedback inhibition. Addict Biol. 2008;13(1):118–23. doi: 10.1111/j.1369-1600.2007.00072.x. [DOI] [PubMed] [Google Scholar]
- 27.Stefano GB, Cadet P, Kream RM, Zhu W. The presence of endogenous morphine signaling in animals. Neurochem Res. 2008;33(10):1933–39. doi: 10.1007/s11064-008-9674-0. [DOI] [PubMed] [Google Scholar]
- 28.Stefano GB, Ptacek R, Kuzelova H, Kream RM. Endogenous morphine: Up-to-date review 2011. Folia Biol (Praha) 2012;58(2):49–56. [PubMed] [Google Scholar]
- 29.Stefano GB, Mantione KJ, Capellan L, et al. Morphine stimulates nitric oxide release in human mitochondria. J Bioenerg Biomembr. 2015;47(5):409–17. doi: 10.1007/s10863-015-9626-8. [DOI] [PubMed] [Google Scholar]
- 30.Snyder C, Kream RM, Ptacek R, Stefano GB. Mitochondria, microbiome and their potential psychiatric modulation. Autism Open Access. 2015;5:2. [Google Scholar]
- 31.Ptacek R, Brejlova D, Domkarova L, et al. Autism – a multifaceted diffuse pathology. J Psychiatry. 2015;18:1000315. [Google Scholar]
- 32.Stefano GB, Kream RM. Glycolytic coupling to mitochondrial energy production ensures survival in an oxygen rich environment. Med Sci Monit. 2016;22:2571–75. doi: 10.12659/MSM.899610. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Stefano GB, Challenger S, Kream RM. Hyperglycemia-associated alterations in cellular signaling and dysregulated mitochondrial bioenergetics in human metabolic disorders. Eur J Nutr. 2016;55(8):2339–45. doi: 10.1007/s00394-016-1212-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Stefano GB. Cognition regulated by emotional decision making. Med Sci Monit Basic Res. 2016;22:1–5. doi: 10.12659/MSMBR.897194. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Kream RM, Stefano GB. Endogenous morphine and nitric oxide coupled regulation of mitochondrial processes. Med Sci Monit. 2009;15(12):RA263–68. [PubMed] [Google Scholar]
- 36.Stefano GB, Kream RM. Reciprocal regulation of cellular nitric oxide formation by nitric oxide synthase and nitrite reductases. Med Sci Monit. 2011;17(10):RA221–26. doi: 10.12659/MSM.881972. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Stefano GB, Kream RM. Nitric oxide regulation of mitochondrial processes: Commonality in medical disorders. Ann Transplant. 2015;20:402–7. doi: 10.12659/AOT.894289. [DOI] [PubMed] [Google Scholar]
- 38.Stefano GB, Kream RM. Dysregulated mitochondrial and chloroplast bioenergetics from a translational medical perspective (Review) Int J Mol Med. 2016;37:547–55. doi: 10.3892/ijmm.2016.2471. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Stefano GB, Samuel J, Kream RM. Antibiotics may trigger mitochondrial dysfunction inducing psychiatric disorders. Med Sci Monit. 2017;23:101–6. doi: 10.12659/MSM.899478. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Betina V. The use of antibiotics for studies of morphogenesis and differentiation in microorganisms. Folia Microbiol (Praha) 1980;25(6):505–23. doi: 10.1007/BF02897219. [DOI] [PubMed] [Google Scholar]
- 41.Stefano GB, Kream RM. Mitochondrial DNA heteroplasmy in human health and disease. Biomed Rep. 2016;4:259–62. doi: 10.3892/br.2016.590. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Stefano GB, Bjenning C, Wang F, et al. In: Mitochondrial heteroplasmy, in mitochondria in cardiovascular medicine. Santulli G, editor. Springer-Nature; 2017. [in press] [Google Scholar]
- 43.Abouesh A, Stone C, Hobbs WR. Antimicrobial-induced mania (antibiomania): A review of spontaneous reports. J Clin Psychopharmacol. 2002;22(1):71–81. doi: 10.1097/00004714-200202000-00012. [DOI] [PubMed] [Google Scholar]
- 44.Ben-Chetrit E, Rothstein N, Munter G. Ciprofloxacin-induced psychosis. Antimicrob Agents Chemother. 2013;57(8):4079. doi: 10.1128/AAC.00672-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Mulhall JP, Bergmann LS. Ciprofloxacin-induced acute psychosis. Urology. 1995;46(1):102–3. doi: 10.1016/S0090-4295(99)80171-X. [DOI] [PubMed] [Google Scholar]
- 46.Reeves RR. Ciprofloxacin-induced psychosis. Ann Pharmacother. 1992;26(7–8):930–31. doi: 10.1177/106002809202600716. [DOI] [PubMed] [Google Scholar]
- 47.Murray GK, Corlett PR, Clark L, et al. Substantia nigra/ventral tegmental reward prediction error disruption in psychosis. Mol Psychiatry. 2008;13(3):239, 267–76. doi: 10.1038/sj.mp.4002058. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Khandheria M, Snook E, Thomas C. Psychotic episode secondary to metronidazole use. Gen Hosp Psychiatry. 2014;36(2):231e3–4. doi: 10.1016/j.genhosppsych.2013.11.009. [DOI] [PubMed] [Google Scholar]
- 49.Koul S, Bhan-Kotwal S, Jenkins HS, Carmaciu CD. Organic psychosis induced by ofloxacin and metronidazole. Br J Hosp Med (Lond) 2009;70(4):236–37. doi: 10.12968/hmed.2009.70.4.41632. [DOI] [PubMed] [Google Scholar]
- 50.Stuhec M. Trimethoprim-sulfamethoxazole-related hallucinations. Gen Hosp Psychiatry. 2014;36(2):230e7–8. doi: 10.1016/j.genhosppsych.2013.10.016. [DOI] [PubMed] [Google Scholar]
- 51.Weis S, Karagulle D, Kornhuber J, Bayerlein K. Cotrimoxazole-induced psychosis: a case report and review of literature. Pharmacopsychiatry. 2006;39(6):236–37. doi: 10.1055/s-2006-950393. [DOI] [PubMed] [Google Scholar]
- 52.Cummings JL, Barritt CF, Horan M. Delusions induced by procaine penicillin: Case report and review of the syndrome. Int J Psychiatry Med. 1986;16(2):163–68. doi: 10.2190/knqt-ueu4-gaq2-57l6. [DOI] [PubMed] [Google Scholar]
- 53.Dinca EB, Skinner A, Dinca RV, Tudose C. The dangers of gastritis: A case of clarithromycin-associated brief psychotic episode. J Nerv Ment Dis. 2015;203(2):149–51. doi: 10.1097/NMD.0000000000000251. [DOI] [PubMed] [Google Scholar]
- 54.Jimenez P, Navarro-Ruiz A, Sendra P, et al. Hallucinations with therapeutic doses of clarithromycin. Int J Clin Pharmacol Ther. 2002;40(1):20–22. doi: 10.5414/cpp40020. [DOI] [PubMed] [Google Scholar]
- 55.Stefano GB, Kream R. Psychiatric disorders involving mitochondrial processes. Psychology Observer. 2015;1:1–6. [Google Scholar]
- 56.Abildgaard A, Elfving B, Hokland M, et al. Probiotic treatment reduces depressive-like behaviour in rats independently of diet. Psychoneuroendocrinology. 2017;79:40–48. doi: 10.1016/j.psyneuen.2017.02.014. [DOI] [PubMed] [Google Scholar]
- 57.Lin P, Ding B, Feng C, et al. Prevotella and Klebsiella proportions in fecal microbial communities are potential characteristic parameters for patients with major depressive disorder. J Affect Disord. 2017;207:300–4. doi: 10.1016/j.jad.2016.09.051. [DOI] [PubMed] [Google Scholar]
- 58.Majamaa H, Isolauri E. Probiotics: A novel approach in the management of food allergy. J Allergy Clin Immunol. 1997;99(2):179–85. doi: 10.1016/s0091-6749(97)70093-9. [DOI] [PubMed] [Google Scholar]
- 59.Khanna S, Tosh PK. A clinician’s primer on the role of the microbiome in human health and disease. Mayo Clin Proc. 2014;89(1):107–14. doi: 10.1016/j.mayocp.2013.10.011. [DOI] [PubMed] [Google Scholar]
- 60.Kelly JR, Borre Y, O’Brien C, et al. Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat. J Psychiatr Res. 2016;82:109–18. doi: 10.1016/j.jpsychires.2016.07.019. [DOI] [PubMed] [Google Scholar]
- 61.Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent clostridium difficile infection: A randomized trial. Ann Intern Med. 2016;165(9):609–16. doi: 10.7326/M16-0271. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Evrensel A, Ceylan ME. Fecal microbiota transplantation and its usage in neuropsychiatric disorders. Clin Psychopharmacol Neurosci. 2016;14(3):231–37. doi: 10.9758/cpn.2016.14.3.231. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Evrensel A, Ceylan ME. [The future of fecal microbiota transplantation method in neuropsychiatric disorders]. Turk Psikiyatri Derg. 2016;27(1):71–72. [in Turkish] [PubMed] [Google Scholar]
- 64.Dinan TG, Cryan JF. Microbes, immunity, and behavior: Psychoneuro-immunology meets the microbiome. Neuropsychopharmacology. 2017;42(1):178–92. doi: 10.1038/npp.2016.103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Borre YE, Moloney RD, Clarke G, et al. The impact of microbiota on brain and behavior: Mechanisms & therapeutic potential. Adv Exp Med Biol. 2014;817:373–403. doi: 10.1007/978-1-4939-0897-4_17. [DOI] [PubMed] [Google Scholar]
- 66.Petra AI, Panagiotidou S, Hatziagelaki E, et al. Gut-microbiota-brain axis and its effect on neuropsychiatric disorders with suspected immune dysregulation. Clin Ther. 2015;37(5):984–95. doi: 10.1016/j.clinthera.2015.04.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Zhou L, Foster JA. Psychobiotics and the gut-brain axis: In the pursuit of happiness. Neuropsychiatr Dis Treat. 2015;11:715–23. doi: 10.2147/NDT.S61997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Kosikowska U, Biernasiuk A, Korona-Glowniak I, et al. The association of chronic hepatitis C with respiratory microbiota disturbance on the basis of decreased Haemophilus Spp. colonization. Med Sci Monit. 2016;22:625–32. doi: 10.12659/MSM.895544. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Ding W, Xu C, Wang B, Zhang M. Rotenone attenuates renal injury in aldosterone-infused rats by inhibiting oxidative stress, mitochondrial dysfunction, and inflammasome activation. Med Sci Monit. 2015;21:3136–43. doi: 10.12659/MSM.895945. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Jing L, Li Q, He L, et al. Protective effect of tempol against hypoxia-induced oxidative stress and apoptosis in H9c2 cells. Med Sci Monit Basic Res. 2017;23:159–65. doi: 10.12659/MSMBR.903764. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Samak M, Fatullayev J, Sabashnikov A, et al. Cardiac hypertrophy: An introduction to molecular and cellular basis. Med Sci Monit Basic Res. 2016;22:75–79. doi: 10.12659/MSMBR.900437. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Frye RE, Slattery J, MacFabe DF, et al. Approaches to studying and manipulating the enteric microbiome to improve autism symptoms. Microb Ecol Health Dis. 2015;26:26878. doi: 10.3402/mehd.v26.26878. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Frye RE, Rose S, Slattery J, MacFabe DF. Gastrointestinal dysfunction in autism spectrum disorder: The role of the mitochondria and the enteric microbiome. Microb Ecol Health Dis. 2015;26:27458. doi: 10.3402/mehd.v26.27458. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Ptacek R, Kuzelova H, Stefano GB. Dopamine D4 receptor gene DRD4 and its association with psychiatric disorders. Med Sci Monit. 2011;17(9):RA215–20. doi: 10.12659/MSM.881925. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Ptacek R, Kuzelova H, Stefano GB. Genetics in psychiatry – up-to-date review 2011. Neuro Endocrinol Lett. 2011;32(4):389–99. [PubMed] [Google Scholar]
- 76.Kuzelova H, Ptacek R, Macek M. The serotonin transporter gene (5-HTT) variant and psychiatric disorders: Review of current literature. Neuro Endocrinol Lett. 2010;31(1):4–10. [PubMed] [Google Scholar]
- 77.Davidson JR. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry. 2010;71(Suppl E1):e04. doi: 10.4088/JCP.9058se1c.04gry. [DOI] [PubMed] [Google Scholar]
- 78.Boschloo L, Reeuwijk KG, Schoevers RA, W J H Penninx B. The impact of lifestyle factors on the 2-year course of depressive and/or anxiety disorders. J Affect Disord. 2014;159:73–79. doi: 10.1016/j.jad.2014.01.019. [DOI] [PubMed] [Google Scholar]
- 79.Lopresti AL, Hood SD, Drummond PD. A review of lifestyle factors that contribute to important pathways associated with major depression: Diet, sleep and exercise. J Affect Disord. 2013;148(1):12–27. doi: 10.1016/j.jad.2013.01.014. [DOI] [PubMed] [Google Scholar]